Digitally Transforming Pharmacovigilance Processes Requires a Careful Balance between Technology, Economics, and Humanity

Aug 12, 2020

On June 9th, 2020 ArisGlobal held a webinar titledPharmacovigilance and Digital Transformation: Stepping into the Technology-Driven Future.” During the webinar, over half (58%) of attendees indicated that they are no longer relying on Microsoft Excel workbooks to manage case activities such as allocation, workflow management and query tracking. ArisGlobal has noted a continuous trend away from manual processes. On October 15th of 2019, for example, during ArisGlobal’s, Automation in Pharmacovigilance: From Hype to Reality” webinar, nearly half (43%) of all respondents considered automation of pharmacovigilance (PV) processes to be a top priority for their organizations.  

The webinar, presented by Aman Wasan, Senior Vice President, Global Pharmacovigilance for ArisGlobal explored the perceived barriers toward adopting next-generation technologies in PV. The responses were varied, with budget being the biggest reason at thirty-eight percent (38%), followed by resistance to change at twenty-eight percent (28%), expertise at twenty-two percent (22%), and only twelve percent (12%) of the respondents believed it is awareness.

ArisGlobal believes that adopting next-generation technologies to support pharmacovigilance processes requires a careful balance between technology, economics, and humanity. It is no surprise to see budgetary concerns as the top barrier toward adoption. Technology requires investment and that investment must be done carefully. However, it is interesting to see the human side of technology adoption, “resistance to change” as the second highest concern.  Ultimately, digital transformation strongly transforms people’s day-to-day processes. If companies recognize this and address it properly, such as with thoughtful training, they can adopt technology in a faster, more seamless, and expedited way. 

ArisGlobal’s LifeSphere MultiVigilance 10 is the only automated, end-to-end safety system built with the industry, for the industry, and developed in partnership with the world’s best life sciences companies. Contact us today to find out how LifeSphere Multivigilance 10 can help your Pharmacovigilance team, or visit our product page

To learn more about the questions highlighted in this blog series, view the on-demand webinar Pharmacovigilance and Digital Transformation: Stepping into the Technology-Driven Future. 

To find out more about how LifeSphere Multivigilance helps SMBs manage and master pharmacovigilance, read our blog here

(This is Blog #2 in a two-part series from the Pharmacovigilance and Digital Transformation: Stepping into the Technology-Driven Future webinar.) 


About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn:
Follow @Aris_Global on Twitter:


Erika Thomas
+305-726-6601 |